 New York, April 26, 2021 GLOBE NEWSWIRE -- Protagenic Therapeutics, Inc. NASDAQ:PTIX PTIX or Company today announced the pricing of an underwritten public offering of 3,180,000 units at a public offering price of 4.15 per unit for aggregate gross proceeds of approximately 13.2 million prior to deducting underwriting discounts, commissions, and other offering expenses. Each unit is comprised of one share of common stock and one warrant to purchase one share of common stock. Each warrant is exercisable for one share of common stock at an exercise price of 4.98 per share and will expire five years from issuance. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 477,000 units at the public offering price less the underwriting discounts and commissions. The offering is expected to close on or around April 29, 2021, subject to satisfaction of customary closing conditions. 